Although Amgen has outpaced the Dow over the past year, analysts remain cautiously optimistic about the stock’s prospects.

Amgen (NASDAQ:AMGN) executives outlined the company’s oncology research and development priorities and provided updates on ...

Amgen Inc. (NASDAQ:AMGN) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. On February 20, Barclays initiated ...

Amgen’s Lumakras receives US FDA approval for patients with KRAS G12C-mutated locally advanced or metastatic NSCLC: Thousand Oaks, California Monday, May 31, 2021, 11:00 Hrs [IS ...

Amgen Inc. has reached a significant milestone as its stock hit an all-time high of 385.63 USD, with shares currently trading at $386.08, just shy of the 52-week high of $385.12. This achievement ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

When measured against the market's most prolific capital-return leaders, Amgen’s ability to maintain this level of distribution while simultaneously ...

But Amgen’s true success stems from putting people first. By creating an environment where innovation, inclusion and ...

Amgen on Tuesday said its experimental weight loss injection helped patients with obesity lose up to 20% of their weight on average after a year in a critical mid-stage trial, as the company races to ...

Piper Sandler Virtual Novel Targets in Immunology Symposium February 12, 2026 5:00 PM ESTCompany ParticipantsPaul Burton - Senior VP ...

Roughly a year and a half after the introduction of a shareholder lawsuit, Amgen has lost its bid to toss the case accusing the California biotech giant of concealing a massive tax bill with the IRS.

Compared to the aggregate P/E ratio of the 83.91 in the Biotechnology industry, Amgen Inc. has a lower P/E ratio of 26.69. Shareholders might be inclined to think that the stock might perform worse ...